Figure 5
From: Reduced Skin Blistering in Experimental Epidermolysis Bullosa Acquisita After Anti-TNF Treatment
Therapeutic application of ETA improved disease severity in immunization-induced EBA. Three to six weeks after B6.S mice were immunized with mCOL7C-GST in TiterMax, mice developed clinical disease with more than 2% affected skin and were allocated into either the PBS (n = 7) or ETA (n = 8) treatment group. Representative clinical pictures of mice at 6 wks of treatment that received (A,B) PBS or (C,D) ETA every second day for 6 wks. (E) Time course of clinical disease development, shown as percentage of body surface area affected by blistering and (F) as area under the curve calculated over time for the entire treatment period of 6 wks (*p < 0.05, **p < 0.01).